Scholars Central

Research articlePublished 2010

Concomitant Nevirapine Therapy is Associated with Higher Efficacy of Pegylated Interferon Plus Ribavirin among HIV/ Hepatitis C Virus-Coinfected Patients

Authors: Jose A. Mira, Luis F. Lopez-Cortes, Eugenia Vispo, Cristina Tural, Montserrat Laguno, Elena Ferrer, Ignacio de los Santos-Gil, Pere Domingo, Hernando Knobel, Francisco Tellez, Manuel Crespo, Antonio Rivero, Enrique Ortega, Juan A. Pineda

Journal of AIDS & Clinical Research

Volume 1 · Issue 3 · Pages 1–8

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Objective: To determine the influence of nevirapine (NVP) and lopinavir/ritonavir (LPV/r) on the efficacy of pegylated interferon (peg-IFN) plus ribavirin (RBV) among HIV/HCV-coinfected patients. Methods: All HIV/HCV-coinfected patients who received peg-IFN plus RBV while under a three-drug antiretroviral regimen including tenofovir (TDF) plus lamivudine (3TC) or emtricitabine (FTC) along with NVP or along with LPV/r at twenty hospitals in Spain were included in this retrospective study. Sustained virological response (SVR) rates in both groups were compared. Results: A total of 165 patients were included in the study, 71 (43%) receiving NVP and 94 (57%) LPV/r. Significantly more patients on LPV/r had a baseline HCV-RNA load ≥600000 IU/mL (44% vs. 73%, p=0.001). Forty (56%) individuals included in the NVP group and 35 (37%) in the LPV/r group showed SVR (p=0.015). In the NVP group, 19 (43%) patients carrying genotype 1-4 and 21 (78%) subjects with genotype 2-3 achieved SVR. In the LPV/r group, the corresponding figures were 25% (p=0.04) and 59% (p=0.1). In the subpopulation of individuals with baseline HCV viral load ≥600,000 IU/mL, 18 (58%) of those taking NVP vs. 21 (31%) who were given LPV/r reached SVR (p=0.01). HCV genotype 2-3, adherence to HCV therapy >80% and use of NVP during peg-IFN plus RBV were independently associated with SVR in the multivariate analysis. Conclusions: HIV/HCV-coinfected patients who receive NVP respond better to peg-IFN plus RBV than those individuals receiving LPV/r. Lower HCV viral load due to NVP treatment may account for the former differences.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of AIDS & Clinical Research.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of AIDS & Clinical Research
  • SubjectInfectious Diseases
  • BylineArticles whose byline prints “Jose A. Mira”
  • BylineArticles whose byline prints “Luis F. Lopez-Cortes”
  • BylineArticles whose byline prints “Eugenia Vispo”
  • BylineArticles whose byline prints “Cristina Tural”
  • BylineArticles whose byline prints “Montserrat Laguno”
  • BylineArticles whose byline prints “Elena Ferrer”
  • BylineArticles whose byline prints “Ignacio de los Santos-Gil”
  • BylineArticles whose byline prints “Pere Domingo”